KR20210091430A - Cosmetic composition containing natural complex extracts as active ingredient - Google Patents

Cosmetic composition containing natural complex extracts as active ingredient Download PDF

Info

Publication number
KR20210091430A
KR20210091430A KR1020200004587A KR20200004587A KR20210091430A KR 20210091430 A KR20210091430 A KR 20210091430A KR 1020200004587 A KR1020200004587 A KR 1020200004587A KR 20200004587 A KR20200004587 A KR 20200004587A KR 20210091430 A KR20210091430 A KR 20210091430A
Authority
KR
South Korea
Prior art keywords
cosmetic composition
extract
activity
skin
composition
Prior art date
Application number
KR1020200004587A
Other languages
Korean (ko)
Other versions
KR102343705B1 (en
Inventor
김범수
이진영
Original Assignee
김범수
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 김범수 filed Critical 김범수
Priority to KR1020200004587A priority Critical patent/KR102343705B1/en
Publication of KR20210091430A publication Critical patent/KR20210091430A/en
Application granted granted Critical
Publication of KR102343705B1 publication Critical patent/KR102343705B1/en

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783Angiosperms [Magnoliophyta]
    • A61K8/9789Magnoliopsida [dicotyledons]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • A61Q19/02Preparations for care of the skin for chemically bleaching or whitening the skin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • A61Q19/08Anti-ageing preparations
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/52Stabilizers
    • A61K2800/522Antioxidants; Radical scavengers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/59Mixtures
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/74Biological properties of particular ingredients
    • A61K2800/78Enzyme modulators, e.g. Enzyme agonists
    • A61K2800/782Enzyme inhibitors; Enzyme antagonists

Abstract

The present invention relates to a cosmetic composition for antioxidant, skin whitening, anti-wrinkle or skin inflammatory disease alleviation purposes comprising a natural complex extract as an active ingredient and, more particularly, to a cosmetic composition for antioxidant, skin whitening, anti-wrinkle or skin inflammatory disease alleviation purposes, comprising extracts of Sambucus sieboldiana leaves and Hydrangea macrophylla leaves as active ingredients. The cosmetic composition according to the present invention can exhibit an antioxidant effect that inhibits the activity of DPPH, ABTS, and superoxide anion radicals and a whitening effect through a mechanism of inhibiting the expression of tyrosinase or the like, and can exhibit an anti-inflammatory effect through a mechanism of inhibiting the expression of NO, iNOS, and COX-2.

Description

천연 복합 추출물을 유효성분으로 포함하는 화장료 조성물{Cosmetic composition containing natural complex extracts as active ingredient}Cosmetic composition containing natural complex extracts as active ingredient}

본 발명은 천연 복합 추출물을 유효성분으로 포함하는 항산화, 피부 미백, 주름 개선 또는 피부 염증성 질환 개선용 화장료 조성물에 관한 것으로, 보다 상세하게는 말오줌나무잎 추출물 및 수국잎 추출물을 유효성분으로 포함하는 항산화, 피부 미백, 주름 개선 또는 피부 염증성 질환 개선용 화장료 조성물에 관한 것이다.The present invention relates to a cosmetic composition for antioxidant, skin whitening, wrinkle improvement or skin inflammatory disease improvement comprising a natural complex extract as an active ingredient. It relates to a cosmetic composition for antioxidation, skin whitening, wrinkle improvement, or skin inflammatory disease improvement.

최근 경제 발전에 따른 의료기술의 발달 및 평균수명의 연장으로 고령자 비율이 계속하여 증가하고 있으며, 환경오염 및 스트레스 증가에 따른 면역계 이상으로 염증반응의 만성화가 진행되어 아토피, 천식 등의 만성 염증성 질환이 증가하고 있는 추세이다.The proportion of the elderly continues to increase due to the development of medical technology and the extension of life expectancy due to the recent economic development, and chronic inflammatory reactions such as atopy and asthma are increasing due to the chronic inflammatory response due to the immune system abnormality due to the increase in environmental pollution and stress. It is an increasing trend.

일반적으로 염증반응은 세균감염과 같은 외부자극이나 생체 내 대사산물과 같은 내부자극에 대한 생체조직의 방어기전으로 세포 내 다양한 염증조절인자들인 TNF-α, IL-1β, IL-6 등과 같은 여러 사이토카인(cytokine) 및 산화질소(nitric oxide, NO)가 생성되면서 발생한다. 또한, 내독소로 알려진 지질다당체(lipopolysaccharide, LPS)는 그람 음성균의 세포 외막에 존재하여, 대식세포 또는 단핵세포에서 세포내 전사요소인 NF-κB(nuclearfacter-κB)의 활성화를 유도함으로써 염증성 사이토카인, iNOS(inducible nitric oxide synthase), COX2(cyclooxygenase-2)의 유전자 발현을 유도하며 염증 매개물질을 생성한다.In general, the inflammatory response is a defense mechanism of living tissues against external stimuli such as bacterial infection or internal stimuli such as in vivo metabolites. It is caused by the production of cytokines and nitric oxide (NO). In addition, lipopolysaccharide (LPS), also known as endotoxin, is present in the outer membrane of Gram-negative bacteria and induces activation of NF-κB (nuclearfactor-κB), an intracellular transcription factor, in macrophages or mononuclear cells, thereby becoming an inflammatory cytokine , iNOS (inducible nitric oxide synthase), COX2 (cyclooxygenase-2) inducing gene expression and generating mediators of inflammation.

따라서 염증반응의 조절을 위해서는 iNOS, COX-2, 및 사이토카인과 산화질소의 분비를 조절하는 것이 핵심요소이며, 이와 같은 인자들의 활성을 조절하는 물질이 염증질환의 예방 및 치료제로서 주목받고 있다.Therefore, in order to control the inflammatory response, iNOS, COX-2, and cytokines and nitric oxide are key factors to control, and substances that control the activity of these factors are attracting attention as preventive and therapeutic agents for inflammatory diseases.

한편, 자외선(ultraviolet rays; UV)에 노출되면 피부에서는 활성 산소종(ROS, reactive oxygen species)이 생성되고, 과잉 생성된 활성산소는 산화작용을 일으켜 세포막, DNA 그리고 피부의 주요 구성물질인 지질, 단백질, 다당류 및 핵산과 반응하여 세포에 손상을 주고 피부 노화를 발생시키는 원인이 된다. 이러한 활성산소를 억제하는 성분으로는 butylated hydroxy anisol(BHA), butylated hydroxy toluene(BHT) 등이 알려져 있다.On the other hand, when exposed to ultraviolet rays (UV), reactive oxygen species (ROS) are generated in the skin, and the excess reactive oxygen species causes oxidation, resulting in cell membranes, DNA, and lipids, which are the main components of the skin. It reacts with proteins, polysaccharides and nucleic acids to damage cells and cause skin aging. As a component that inhibits these free radicals, butylated hydroxy anisol (BHA), butylated hydroxy toluene (BHT), and the like are known.

또한 UV는 멜라닌 생성을 촉진시키는 것으로 알려져 있는데, 멜라닌은 피부 표피의 기저층에 존재하는 멜라노사이트라는 세포에서 티로신(Tyrosine)이 효소 및 비효소적 산화반응을 거쳐 생성되며, 표피를 구성하고 있는 각질세포로 전이된다. 멜라닌의 생합성에 관여하는 중요한 효소로는 티로시나제(Tyrosinase), 티로시나제 관련 프로테인1(Tyrosinase-Related protein 1) 및 도파크롬 토토머라제(dopachrome tautomerase)가 있다. 티로시나제 외의 이 두 효소는 주목을 끌고 있으나 멜라닌 합성에 결정적인 역할을 하는 효소는 티로시나제이다. 멜라닌의 생합성 첫 단계는 티로시나제에 의하여 유발된다. 티로시나제에 의해 티로신이 도파(Dopa)로 되고, 이 도파(Dopa)를 도파퀴논(Dopa-quinone)으로 만든다.In addition, UV is known to promote melanin production. Melanin is produced through enzymatic and non-enzymatic oxidation reactions of tyrosine in cells called melanocytes present in the basal layer of the epidermis, keratinocytes constituting the epidermis. is transferred to Important enzymes involved in the biosynthesis of melanin include tyrosinase, tyrosinase-related protein 1, and dopachrome tautomerase. Besides tyrosinase, these two enzymes are attracting attention, but the enzyme that plays a crucial role in melanin synthesis is tyrosinase. The first step in the biosynthesis of melanin is induced by tyrosinase. Tyrosine is converted to dopa by tyrosinase, and this dopa is converted to dopa-quinone.

이 두 반응의 다음단계 과정들은 비효소적인 반응에 의해서도 가능한 것으로 알려져 있으며 티로시나제 단독으로도 멜라닌 생성이 가능하다고 알려져 있다.The next steps of these two reactions are known to be possible by non-enzymatic reactions, and it is known that melanin production is possible even with tyrosinase alone.

한편, 항염의 목적으로 이용되고 있는 물질로는 비스테로이드 계통인 플루페나믹산(flufenamic acid), 이부프로펜(ibuprofen), 벤지다민(benzydamine), 인도메타신(indomethacin); 스테로이드 계통으로 프레드니솔론(prednisolone), 덱사메타손(dexamethasone), 하이드로코티손(hydrocortisone), 베타메타손(betamethasone) 등이 있으나, 이들 물질은 독성이 강하며, 간 손상, 암, 뇌졸중과 같은 여러 심각한 부작용을 초래하여 사용시 제한이 따른다. 또한, 염증 원인 물질에 선택적으로 작용하지 못하여 심한 면역억제를 유발하는 문제가 생기는 경우도 있다. 이에 생체에 안전하고, 종래 의약품에 비해 장기간 섭취가 용이한 장점을 가지고 있는 다양한 천연물을 이용한 염증 치료제의 개발이 이루어지고 있다.On the other hand, the substances used for the purpose of anti-inflammatory flufenamic acid (flufenamic acid), ibuprofen (ibuprofen), benzydamine (benzydamine), indomethacin (indomethacin), which are non-steroidal type; Steroids include prednisolone, dexamethasone, hydrocortisone, and betamethasone, but these substances are highly toxic and cause serious side effects such as liver damage, cancer, and stroke. Restrictions follow. In addition, there are cases in which a problem of inducing severe immunosuppression occurs because it cannot selectively act on substances that cause inflammation. Accordingly, the development of anti-inflammatory drugs using various natural products that are safe to the living body and have the advantage of being easy to consume for a long period of time compared to conventional drugs is being developed.

한국등록특허 제1492074호에는 수국 추출물을 유효성분으로 함유하는 피부 미백용 조성물이 개시되어 있으나, 기존의 조성물보다 우수한 항산화, 피부 미백, 주름 개선, 항염증 활성을 지닌 성분의 개발이 지속적으로 요구되고 있으며, 동시에 적용되어 시너지를 발휘할 수 있는 다양한 성분들의 조합 또는 추출 방법등의 개발이 요구되고 있다Korea Patent No. 1492074 discloses a composition for skin whitening containing hydrangea extract as an active ingredient, but the development of a component with antioxidant, skin whitening, wrinkle improvement, and anti-inflammatory activity superior to existing compositions is continuously required. It is required to develop a combination or extraction method of various ingredients that can be applied at the same time to exert synergy.

한국등록특허 제10-1492074호Korean Patent Registration No. 10-1492074

본 발명자들은 항산화, 피부 미백, 주름 개선, 피부 염증성 질환 개선을 위한 천연 추출물들을 발굴하기 위한 연구를 진행하던 중, 말오줌나무잎 추출물 및 수국잎 추출물의 혼합물이 우수한 효과를 나타냄을 확인하여 본 발명을 완성하였다.The inventors of the present invention confirmed that a mixture of oleifera leaf extract and hydrangea leaf extract showed excellent effects while conducting research to discover natural extracts for antioxidant, skin whitening, wrinkle improvement, and skin inflammatory disease improvement. was completed.

따라서, 본 발명의 목적은 말오줌나무잎 추출물 및 수국잎 추출물을 유효성분으로 포함하는 항산화, 피부 미백, 주름 개선 또는 피부 염증성 질환 개선용 화장료 조성물을 제공하는 것이다.Accordingly, an object of the present invention is to provide a cosmetic composition for antioxidation, skin whitening, wrinkle improvement, or skin inflammatory disease improvement, comprising an extract of horse chestnut leaf extract and hydrangea leaf extract as active ingredients.

상기 목적을 달성하기 위하여, 본 발명은 말오줌나무잎 추출물 및 수국잎 추출물을 유효성분으로 포함하는 항산화, 피부 미백, 주름 개선 또는 피부 염증성 질환 개선용 화장료 조성물을 제공한다. In order to achieve the above object, the present invention provides a cosmetic composition for anti-oxidation, skin whitening, wrinkle improvement or skin inflammatory disease improvement, comprising an extract of horse chestnut leaf extract and hydrangea leaf extract as active ingredients.

또한, 상기 추출물은 물, C1 ~ C4의 알코올, 프로필렌글리콜, 부틸렌글리콜, 글리세린, 아세톤, 에틸 아세테이트, 클로로포름, 부틸 아세테이트, 디에틸에테르, 디클로로메탄, 헥산 또는 이들의 혼합물을 용매로 사용하여 추출한 것일 수 있다. In addition, the extract is water, C 1 ~ C 4 alcohol, propylene glycol, butylene glycol, glycerin, acetone, ethyl acetate, chloroform, butyl acetate, diethyl ether, dichloromethane, hexane or a mixture thereof is used as a solvent may have been extracted.

또한, 상기 말오줌나무잎 추출물 및 수국잎 추출물은 1 : 0.1 ~ 10 중량비로 포함될 수 있다. In addition, the horse pee tree leaf extract and hydrangea leaf extract may be included in a weight ratio of 1: 0.1 to 10.

또한, 본 발명의 화장료 조성물은 DPPH(1-1-diphenyl-2-picryl-hydrazyl), ABTS(2,2'-azino-bis-3-ethylbenzothiazoline-6-sulphonic acid) 라디칼(radical) 또는 슈퍼옥사이드 음이온 라디칼(superoxide anion radical) 활성을 저해할 수 있고, 티로시나아제(Tyrosinase), 엘라스타아제(Elastase), 콜라게나아제(Collagenase)의 발현을 억제할 수 있으며, NO(nitric oxide), iNOS(inducible nitric oxide synthase) 또는 COX-2(cyclooxygenase-2)의 발현을 억제할 수 있다. In addition, the cosmetic composition of the present invention is DPPH (1-1-diphenyl-2-picryl-hydrazyl), ABTS (2,2'-azino-bis-3-ethylbenzothiazoline-6-sulphonic acid) radical (radical) or superoxide Can inhibit the activity of superoxide anion radical, can inhibit the expression of tyrosinase, elastase, collagenase, NO (nitric oxide), iNOS ( It can inhibit the expression of inducible nitric oxide synthase) or cyclooxygenase-2 (COX-2).

본 발명에 따른 화장료 조성물은 DPPH, ABTS, 슈퍼옥사이드 음이온 라디칼의 활성을 억제하는 항산화효과와 티로시나아제 등의 발현을 저해하는 기작을 통하여 미백 효과를 나타낼 수 있고, NO, iNOS, COX-2 의 발현을 억제하는 기작을 통하여 항염증 효과를 나타낼 수 있다. The cosmetic composition according to the present invention can exhibit a whitening effect through an antioxidant effect that inhibits the activity of DPPH, ABTS, and superoxide anion radicals and a mechanism of inhibiting the expression of tyrosinase, etc. An anti-inflammatory effect can be exhibited through a mechanism of suppressing expression.

따라서 본 발명에 따른 조성물은 피부에 자극을 일으키지 않는 항산화, 미백, 주름 개선 또는 피부 염증성 질환 개선을 위한 기능성 화장품의 소재로 유용하게 사용될 수 있다. Therefore, the composition according to the present invention can be usefully used as a material for functional cosmetics for anti-oxidation, whitening, wrinkle improvement, or skin inflammatory disease improvement that does not cause irritation to the skin.

도 1은 Western blot을 통하여 실시예 1의 조성물이 iNOS, COX-2의 활성에 미치는 영향을 확인한 사진 및 그래프이다((A) iNOS, (B) COX-2).
도 2는 RT-PCR을 통하여 실시예 1의 조성물이 iNOS, COX-2의 활성에 미치는 영향을 확인한 사진 및 그래프이다((A) iNOS, (B) COX-2).
1 is a photograph and graph confirming the effect of the composition of Example 1 on the activity of iNOS and COX-2 through Western blot ((A) iNOS, (B) COX-2).
2 is a photograph and graph confirming the effect of the composition of Example 1 on the activity of iNOS and COX-2 through RT-PCR ((A) iNOS, (B) COX-2).

이하, 본 발명을 상세히 설명한다. 본 명세서 및 청구범위에 사용되는 용어나 단어는 통상적이거나 사전적인 의미로 한정해서 해석되어서는 아니되며, 발명자는 그 자신의 발명을 가장 최선의 방법으로 설명하기 위해 용어의 개념을 적절하게 정의할 수 있다는 원칙에 입각하여 본 발명의 기술적 사상에 부합하는 의미와 개념으로 해석되어야만 한다.Hereinafter, the present invention will be described in detail. The terms or words used in the present specification and claims should not be construed as being limited to ordinary or dictionary meanings, and the inventor may properly define the concept of the term in order to best describe his invention. It should be interpreted as meaning and concept consistent with the technical idea of the present invention based on the principle that there is.

본 발명은 말오줌나무잎 추출물 및 수국잎 추출물을 유효성분으로 포함하는 항산화, 피부 미백, 주름 개선 또는 피부 염증성 질환 개선용 화장료 조성물을 제공한다. The present invention provides a cosmetic composition for antioxidation, skin whitening, wrinkle improvement, or skin inflammatory disease improvement, comprising an extract of horse chestnut tree leaf and hydrangea leaf extract as active ingredients.

말오줌나무(Sambucus sieboldiana var. pendula)는 수접골목, 울릉딱총나무, 말오줌대 또는 말오좀대라고도 하며, 한국 울릉도 해발 900m이하 산지 계곡에 자생한다. 낙엽관목이며 높이 2 ~ 4 m로서 줄기에 코르코가 발달하고 어린가지에 털이 없다. 잎은 대생하고 2 ~ 3쌍의 소엽으로 구성된 기수1회우상복엽이다. 잎은 길이 10 ~ 15cm, 너비 5 ~ 6cm이고 앙면에 털이 없으며 가장자리의 톱니가 안으로 굽는다. 5 ~ 6월에 꽃이 피고 꽃은 황백색이며, 열매는 7월에 붉은 색으로 익고 3 ~ 4개의 종자가 들어 있다. Sambucus sieboldiana var. pendula ) is also known as Suap Alley, Ulleung Elderly, or Malophosa, and grows wild in mountain valleys below 900 m above sea level in Ulleungdo, Korea. It is a deciduous shrub, 2 ~ 4 m in height, with cork developed on the stem and hairless on the young branch. The leaves are opposite, and they are radix unilateral, composed of 2-3 pairs of leaflets. The leaf is 10-15cm long and 5-6cm wide, has no hair on the top, and the sawtooth on the edge is bent inward. Flowers bloom from May to June, flowers are yellowish white, and fruits ripen in red in July and contain 3 to 4 seeds.

수국(Hydrangea macrophylla)은 쌍떡잎식물 장미목(Rosales), 수국과(Hydrangeaceae), 수국속(Hydrangea)의 낙엽관목으로, 일본이 원산지이며, 우리나라에서는 주로 남부지방인 제주도, 거제도, 남해안 등지에서 재배되고 있다. 민간에서는 수국의 꽃을 말려 해열제로 사용하기도 하였다. 이외에, 수국은 항말라리아, 항염증, 항산화, 혈압강하, 당뇨 및 당뇨합병증 예방 효과 등이 있는 것으로 알려져 있으며(Kim, D.H., et al., 2017), 수국의 뿌리에는 여러 가지 자가면역 질환의 진행을 억제하는 성분으로 알려져 있는 할로푸지논(halofuginone)이 함유되어 있어 의약품으로도 활용가치가 높은 것으로 알려져 있다. Hydrangea macrophylla is a deciduous shrub of the dicotyledonous plants Rosales, Hydrangeaceae, and Hydrangea. . In folklore, hydrangea flowers were dried and used as an antipyretic. In addition, hydrangeas are known to have antimalarial, anti-inflammatory, antioxidant, blood pressure lowering, diabetes and diabetic complications prevention effects (Kim, DH, et al., 2017), and the roots of hydrangeas have various autoimmune diseases. It contains halofuginone, which is known as an ingredient that suppresses

본 발명에서의 추출물이란 천연물로부터 분리된 활성성분 즉, 목적하는 활성을 보이는 물질을 의미하며, 통상적으로 물, 유기용매 또는 이들의 혼합용매를 이용하는 추출과정으로 제조되며, 물, 유기용매 또는 이들의 혼합용매의 추출액, 이의 건조 분말 또는 이를 이용하여 제형화된 모든 형태를 포함한다. 또한, 상기 추출물에는 상기 추출과정을 거친 추출액을 분획한 것도 포함된다.The extract in the present invention refers to an active ingredient separated from a natural product, that is, a substance exhibiting a desired activity, and is usually prepared by an extraction process using water, an organic solvent, or a mixed solvent thereof, and water, an organic solvent, or a mixture thereof. It includes an extract of a mixed solvent, a dry powder thereof, or any form formulated using the same. In addition, the extract includes fractionation of the extract that has undergone the extraction process.

상기 추출물은 물, C1 ~ C4의 알코올, 프로필렌글리콜, 부틸렌글리콜, 글리세린, 아세톤, 에틸 아세테이트, 클로로포름, 부틸 아세테이트, 디에틸에테르, 디클로로메탄, 헥산 또는 이들의 혼합물을 용매로 사용할 수 있고, 바람직하게는 물, 에탄올, 1,3-부틸렌글리콜을 사용할 수 있으며, 더욱 바람직하게는 50 ~ 90 중량%의 에탄올을 사용할 수 있다. The extract is water, C 1 ~ C 4 alcohol, propylene glycol, butylene glycol, glycerin, acetone, ethyl acetate, chloroform, butyl acetate, diethyl ether, dichloromethane, hexane or a mixture thereof can be used as a solvent and , preferably water, ethanol, 1,3-butylene glycol may be used, and more preferably 50 to 90% by weight of ethanol may be used.

상기 추출물의 추출은 침지 추출, 초임계 추출, 아임계 추출, 고온추출, 고압추출, 환류냉각 추출 및 초음파 추출 등의 방법을 이용할 수 있다.Extraction of the extract may use methods such as immersion extraction, supercritical extraction, subcritical extraction, high temperature extraction, high pressure extraction, reflux cooling extraction, and ultrasonic extraction.

특히, 상기 추출물은 말오줌나무잎, 수국잎을 각각 건조 시킨 후 파쇄한 후 용매를 이용하여 시료의 5 ~ 20 배를 가한 후 침지하여 얻을 수 있다. In particular, the extract can be obtained by immersing the extract after drying 5 to 20 times the amount of the sample using a solvent after drying and crushing the leaves of the hydrangea.

상기 말오줌나무잎 추출물 및 수국잎 추출물은 1 : 0.1 ~ 10의 중량비로 혼합될 수 있고, 바람직하게는 1 : 0.2 ~ 5의 중량비로 혼합될 수 있으며, 가장 바람직하게는 1 : 0.5 ~ 2의 중량비로 혼합될 수 있다. The horse urethra leaf extract and hydrangea leaf extract may be mixed in a weight ratio of 1: 0.1 to 10, preferably in a weight ratio of 1: 0.2 to 5, most preferably 1: 0.5 to 2 It can be mixed by weight ratio.

만일, 상기 추출물의 함량이 상기 기재된 범위를 벗어날 경우 각 성분의 시너지 효과가 저하되어 항산화, 피부 미백, 주름 개선 또는 피부 염증성 질환 개선 활성이 저하될 수 있다.If the content of the extract is out of the range described above, the synergistic effect of each component may be lowered, so that antioxidant, skin whitening, wrinkle improvement or skin inflammatory disease improvement activity may be reduced.

상기 화장료 조성물은 헤어토닉, 헤어컨디셔너, 헤어에센스, 헤어로션, 헤어영양로션, 헤어샴푸, 헤어린스, 헤어트리트먼트, 헤어크림, 헤어영양크림, 헤어모이스처크림, 헤어맛사지크림, 헤어왁스, 헤어 에어로졸, 헤어팩, 헤어영양팩, 헤어비누, 헤어클렌징폼, 머릿기름, 모발건조제, 모발보존처리제, 모발염색제, 모발용 웨이브제, 모발탈색제, 헤어겔, 헤어글레이즈, 헤어드레싱어, 헤어래커, 헤어모이스처라이저, 헤어무스 또는 헤어스프레이의 제형일 수 있으나, 이에 한정되는 것은 아니다.The cosmetic composition is a hair tonic, hair conditioner, hair essence, hair lotion, hair nutrition lotion, hair shampoo, hair conditioner, hair treatment, hair cream, hair nutrition cream, hair moisture cream, hair massage cream, hair wax, hair aerosol , hair pack, hair nutrition pack, hair soap, hair cleansing foam, hair oil, hair dryer, hair preservative, hair dye, hair wave agent, hair bleach, hair gel, hair glaze, hair dresser, hair lacquer, hair moisturizer, It may be in the form of hair mousse or hairspray, but is not limited thereto.

상기 화장료 조성물는 수용성 비타민, 유용성 비타민, 고분자 펩티드, 고분자 다당, 스핑고 지질 및 해초엑기스로 이루어진 군에서 선택된 성분을 포함할 수 있다.The cosmetic composition may include a component selected from the group consisting of water-soluble vitamins, oil-soluble vitamins, high-molecular peptides, high-molecular polysaccharides, sphingolipids, and seaweed extract.

상기 화장료 조성물은은 필요에 따라 통상 화장료에 배합되는 다른 성분을 배합할 수 있다. 첨가할 수 있는 배합 성분으로는 유지 성분, 보습제, 에몰리엔트제, 계면 활성제, 유기 및 무기 안료, 유기 분체, 자외선 흡수제, 방부제, 살균제, 산화 방지제, 식물 추출물, pH 조정제, 알콜, 색소, 향료, 혈행 촉진제, 냉감제, 제한(制汗)제, 정제수 등을 들 수 있다.The cosmetic composition may contain other ingredients that are normally formulated in cosmetics, if necessary. Ingredients that can be added include oils and fats, moisturizers, emollients, surfactants, organic and inorganic pigments, organic powders, UV absorbers, preservatives, fungicides, antioxidants, plant extracts, pH adjusters, alcohols, colorants, fragrances , a blood circulation promoter, a cooling agent, an anti-inflammatory agent, purified water, and the like.

상기 화장료 조성물은 용액, 유화물, 점성형 혼합물 등의 형상을 취할 수 있으며, 화장료 조성물에 통상적으로 이용되는 안정화제, 용해화제, 비타민, 안료 및 향료와 같은 통상적인 보조제 및 담체들을 포함할 수 있다.The cosmetic composition may take the form of a solution, emulsion, viscous mixture, and the like, and may include conventional adjuvants and carriers such as stabilizers, solubilizers, vitamins, pigments and fragrances commonly used in cosmetic compositions.

상기 화장료 조성물은 당업계에서 통상적으로 제조되는 어떠한 제형으로도 제조될 수 있으며, 예를 들어 유액, 크림, 화장수, 팩, 파운데이션, 로션, 미용액, 등을 들 수 있다.The cosmetic composition may be prepared in any formulation conventionally prepared in the art, for example, emulsion, cream, lotion, pack, foundation, lotion, cosmetic liquid, and the like.

본 발명의 화장료 조성물은 DPPH(1-1-diphenyl-2-picryl-hydrazyl), ABTS(2,2'-azino-bis-3-ethylbenzothiazoline-6-sulphonic acid) 라디칼(radical) 또는 슈퍼옥사이드 음이온 라디칼(superoxide anion radical) 활성을 저해할 수 있고, 티로시나아제(Tyrosinase), 엘라스타아제(Elastase), 콜라게나아제(Collagenase)의 발현을 억제할 수 있으며, NO(nitric oxide), iNOS(inducible nitric oxide synthase) 또는 COX-2(cyclooxygenase-2)의 발현을 억제할 수 있다The cosmetic composition of the present invention is DPPH (1-1-diphenyl-2-picryl-hydrazyl), ABTS (2,2'-azino-bis-3-ethylbenzothiazoline-6-sulphonic acid) radical (radical) or superoxide anion radical (superoxide anion radical) activity can be inhibited, can inhibit the expression of tyrosinase, elastase, collagenase, NO (nitric oxide), iNOS (inducible nitric) oxide synthase) or COX-2 (cyclooxygenase-2)

이하, 본 발명을 구체적으로 설명하기 위해 실시예 및 실험예를 들어 상세하게 설명하기로 한다. 그러나 본 발명에 따른 실시예들은 여러 가지 다른 형태로 변형될 수 있으며, 본 발명의 범위가 아래에서 상술하는 실시예들에 한정되는 것으로 해석되어서는 안 된다. 본 발명의 실시예들은 당업계에서 평균적인 지식을 가진 자에게 본 발명을 보다 완전하게 설명하기 위해서 제공되는 것이다.Hereinafter, examples and experimental examples will be described in detail to describe the present invention in detail. However, the embodiments according to the present invention may be modified in various other forms, and the scope of the present invention should not be construed as being limited to the embodiments described below. The embodiments of the present invention are provided to more completely explain the present invention to those of ordinary skill in the art.

<실시예 1> 혼합 추출물의 제조 <Example 1> Preparation of mixed extract

먼저 말오줌나무잎을 건조하여 파쇄한 후, 파쇄한 잎의 10배 중량의 에탄올 용매(70 중량%)에 상온에서 침지시켰다. 24시간 침지 후 실온에서 stirrer(250 rpm)를 이용하여 상등액을 분리하였고, 여과지로 여과하여 고형분을 제 한 후, 여과하여 나온 추출물 건조물을 회전감압농축기를 통해 고농도로 농축하고 -70℃ 에서 농축물을 동결하여 동결건조기를 통해 수분을 완전히 증발시키고 말오줌나무잎 추출물을 획득하였다.First, after drying and crushing the leaves of the horse chestnut tree, it was immersed in an ethanol solvent (70% by weight) 10 times the weight of the crushed leaves at room temperature. After immersion for 24 hours, the supernatant was separated using a stirrer (250 rpm) at room temperature, filtered with a filter paper to remove solids, and the dried extract obtained by filtration was concentrated to a high concentration through a rotary vacuum concentrator and concentrated at -70°C. The water was completely evaporated through a freeze dryer by freezing to obtain a horse urinal leaf extract.

수국잎을 건조하여 파쇄한 후 상기와 동일한 과정을 통하여 수국잎 추출물을 획득하였다. After drying and crushing hydrangea leaves, a hydrangea leaf extract was obtained through the same process as above.

다음, 상기 말오줌나무잎 추출물과 수국잎 추출물을 1 : 1의 중량비로 혼합하여 실험 시료로 사용하였다. Next, the horse urinosa leaf extract and hydrangea leaf extract were mixed in a weight ratio of 1:1 and used as an experimental sample.

<비교예 1> <Comparative Example 1>

상기 제조된 말오줌나무잎 추출물만을 실험 시료로 사용하였다. Only the prepared horse pee tree leaf extract was used as an experimental sample.

<비교예 2> <Comparative Example 2>

상기 제조된 수국잎 추출물만을 실험 시료로 사용하였다. Only the hydrangea leaf extract prepared above was used as an experimental sample.

<실험예 1> 항산화 효능 측정 <Experimental Example 1> Measurement of antioxidant efficacy

항산화 효과를 확인하기 위하여, 전자공여능, ABTS 라디칼 소거활성, SOD 유사 활성을 측정하였다.To confirm the antioxidant effect, electron donating ability, ABTS radical scavenging activity, and SOD-like activity were measured.

<실험예 1-1> 전자공여능 측정<Experimental Example 1-1> Measurement of electron donating ability

전자공여능(EDA: electron donating abilities) 측정 실험은 1,1-diphenyl-2-picrylhydrazyl (DPPH) 60㎕와 1,000 μg/㎖ 농도의 추출물을 120㎕씩 넣고 혼합한 후 15분간 방치한 다음 microplate reader를 이용하여 517nm에서 흡광도를 측정하였다. 전자공여능은 시료용액의 첨가구와 무첨가구의 흡광도 감소율로 나타내었다.For the electron donating abilities (EDA) measurement experiment, 60 μl of 1,1-diphenyl-2-picrylhydrazyl (DPPH) and 120 μl of an extract with a concentration of 1,000 μg/ml were added, mixed, and left for 15 minutes, and then a microplate reader was used. Absorbance was measured at 517 nm using The electron donating ability was expressed as the absorbance decrease rate of the sample solution and the non-additive group.

Figure pat00001
Figure pat00001

상기 전자공여능 측정 결과를 하기 표 1에 나타내었다. The electron donating ability measurement results are shown in Table 1 below.

추출물extract 전자공여능(%)Electron donating ability (%) 실시예 1Example 1 93.593.5 비교예 1Comparative Example 1 86.286.2 비교예 2Comparative Example 2 89.189.1

<실험예 1-2> ABTS 라디칼 소거 활성 측정<Experimental Example 1-2> Measurement of ABTS radical scavenging activity

ABTS 라디칼을 이용한 항산화력 측정은 7 mM 2,2-azino-bis(3-ethyl-benthiazoline-6-sulfonic acid)와 2.45mM potassium persulfate를 혼합하여 실온에서 24시간 동안 보관하여 ABTS+를 형성시킨 후 에탄올로 희석시켜 사용하였으며, ABTS+ 100㎕에 1,000 μg/㎖ 농도의 시료 100㎕를 1:1로 가하여 700nm에서 흡광도를 측정하였다. Antioxidant activity measurement using ABTS radicals was carried out by mixing 7 mM 2,2-azino-bis(3-ethyl-benthiazoline-6-sulfonic acid) and 2.45 mM potassium persulfate and storing them at room temperature for 24 hours to form ABTS + . It was diluted with ethanol, and absorbance was measured at 700 nm by adding 100 μl of a sample having a concentration of 1,000 μg/ml to ABTS + 100 μl in a 1:1 ratio.

Figure pat00002
Figure pat00002

상기 ABTS 라디칼 소거능 측정 결과를 하기 표 2에 나타내었다. The measurement results of the ABTS radical scavenging ability are shown in Table 2 below.

추출물extract ABTS 라디칼 소거능(%)ABTS radical scavenging ability (%) 실시예 1Example 1 94.994.9 비교예 1Comparative Example 1 90.090.0 비교예 2Comparative Example 2 89.189.1

<실험예 1-3> Superoxide dismutase (SOD) 유사활성 측정<Experimental Example 1-3> Superoxide dismutase (SOD)-like activity measurement

SOD 유사활성은 1,000 μg/㎖ 농도의 시료용액을 20 ㎕에 Tris-HCl 완충용액(50mM Tris-HCl buffer, pH 8.5) 130 ㎕와 pyrogallol (7.2mM) 20 ㎕를 취하여 혼합한 후 37℃에서 10분간 반응시킨 후 산화된 pyrogallol양을 microplate reader를 이용하여 흡광도 420 nm에서 측정하였다. SOD 유사활성은 시료용액의 첨가구와 무첨가구의 흡광도감소율로 나타내었다.For SOD-like activity, 130 μl of Tris-HCl buffer (50mM Tris-HCl buffer, pH 8.5) and 20 μl of pyrogallol (7.2mM) were mixed in 20 μl of a 1,000 μg/ml sample solution and mixed at 10°C at 37°C. After reacting for a minute, the amount of oxidized pyrrogallol was measured at absorbance at 420 nm using a microplate reader. The SOD-like activity was expressed as the absorbance reduction rate of the samples with and without the addition of the sample solution.

Figure pat00003
Figure pat00003

상기 SOD 유사 활성 측정 결과를 하기 표 3에 나타내었다. The measurement results of the SOD-like activity are shown in Table 3 below.

추출물extract SOD 유사 활성능(%)SOD-like activity (%) 실시예 1Example 1 55.055.0 비교예 1Comparative Example 1 45.245.2 비교예 2Comparative Example 2 45.545.5

상기 실험을 통하여 실시예 1의 조성물이 말오줌나무잎 추출물, 수국잎 추출물의 단일 추출물에 비하여 우수한 전자공여능, ABTS 라디칼 소거활성, SOD 유사 활성을 나타내어 높은 항산화 활성을 나타내는 것을 확인할 수 있었다. Through the above experiment, it was confirmed that the composition of Example 1 exhibited superior electron donating ability, ABTS radical scavenging activity, and SOD-like activity, compared to single extracts of the extracts of horse urchin leaf extract and hydrangea leaf extract, thereby exhibiting high antioxidant activity.

<실험예 2> 피부 미백 활성 측정 <Experimental Example 2> Measurement of skin whitening activity

피부 미백 활성을 확인하기 위하여 티로시나아제 저해 활성을 측정하였다. 반응구는 67mM sodium phosphate buffer (pH 6.8) 80μl에 10 mM L-DOPA (Sigma, USA)를 녹인 기질액 40 및 1,000 μg/㎖ 농도의시료용액 40 ㎕의 혼합액에 200 U/ml mushroom tyrosinase (Sigma, USA) 40 ㎕을 첨가하여 37℃에서 10분간 반응시켜 반응액 중에 생성된 DOPA chrome을 492 nm에서 측정하였다. 티로시나아제 저해활성은 시료용액의 첨가구와 무첨가구의 흡광도 감소율로 나타내었다.To confirm the skin whitening activity, tyrosinase inhibitory activity was measured. The reaction zone was 200 U/ml mushroom tyrosinase (Sigma, USA) 40 μl was added and reacted at 37° C. for 10 minutes, and DOPA chrome generated in the reaction solution was measured at 492 nm. The tyrosinase inhibitory activity was expressed as the absorbance reduction rate of the group with and without the sample solution.

Figure pat00004
Figure pat00004

상기 티로시나아제 저해 활성 측정 결과를 하기 표 4에 나타내었다. The measurement results of the tyrosinase inhibitory activity are shown in Table 4 below.

추출물extract 티로시나아제 저해 활성(%)Tyrosinase inhibitory activity (%) 실시예 1Example 1 22.622.6 비교예 1Comparative Example 1 8.58.5 비교예 2Comparative Example 2 12.712.7

상기 실험을 통하여 실시예 1의 조성물이 말오줌나무잎 추출물, 수국잎 추출물의 단일 추출물에 비하여 우수한 피부 미백 활성을 나타내는 것을 확인할 수 있었다. Through the above experiment, it was confirmed that the composition of Example 1 exhibited superior skin whitening activity compared to the single extracts of the leaf extract and hydrangea leaf extract.

<실험예 3> 피부 주름 개선 활성 측정 <Experimental Example 3> Measurement of skin wrinkle improvement activity

피부 주름 개선 효과를 확인하기 위하여, 엘라스타아제 저해 활성, 콜라게나아제 저해 활성을 측정하였다. In order to confirm the skin wrinkle improvement effect, elastase inhibitory activity and collagenase inhibitory activity were measured.

<실험예 3-1> 엘라스타아제 저해 활성<Experimental Example 3-1> Elastase inhibitory activity

엘라스타아제 저해활성 측정은 1,000 μg/㎖ 농도의 시험용액을 40㎕씩 96-well plate에 취하고, 50mM tris-HCl buffer (pH8.6)에 녹인 porcine pancreas elastase (2.5U/㎖) 40㎕을 가한다. 기질은 50mM tris-HCl buffer (pH 8.6)에 녹인 N-succinyl-(L-ala)3-p-nitroanilide (0.5mg/㎖)을 80μl 첨가하여 30분간 반응시킨 후 p-nitroanilide의 생성량을 445nm에서 측정하였다. 엘라스타아제 저해활성은 시료용액의 첨가군과 무첨가군의 흡광도 감소율로 나타내었다. For the measurement of elastase inhibitory activity, 40 μl of the test solution at a concentration of 1,000 μg/ml was taken in a 96-well plate, and 40 μl of porcine pancreas elastase (2.5 U/ml) dissolved in 50 mM tris-HCl buffer (pH8.6) was added. apply For the substrate, 80 μl of N-succinyl-(L-ala)3-p-nitroanilide (0.5 mg/ml) dissolved in 50 mM tris-HCl buffer (pH 8.6) was added and reacted for 30 minutes, and the amount of p-nitroanilide was measured at 445 nm. measured. Elastase inhibitory activity was expressed as a decrease in absorbance in the group with and without the sample solution.

Figure pat00005
Figure pat00005

상기 엘라스타아제 저해 활성 측정 결과를 하기 표 5에 나타내었다. The measurement results of the elastase inhibitory activity are shown in Table 5 below.

추출물extract 엘라스타아제 저해 활성(%)Elastase inhibitory activity (%) 실시예 1Example 1 13.613.6 비교예 1Comparative Example 1 6.66.6 비교예 2Comparative Example 2 6.86.8

<실험예 3-2> 콜라게나아제 저해 활성<Experimental Example 3-2> Collagenase inhibitory activity

콜라게나아제 저해활성 측정은 반응구는 0.1M tris-HCl buffer (pH7.5)에 4mM CaCl2를 첨가하여, 4-phenylazobenzyloxycarbonyl-Pro-Leu-Gly-Pro-D-Arg (0.3mg/㎖) (Sigma, U.S.A)를 녹인 기질 액 125㎕와 1,000 μg/㎖ 농도의 시료용액 50㎕의 혼합액에 collagenase (0.2mg/㎖) (Sigma, U.S.A) 75㎕를 첨가하여 실온에서 20분간 방치한다. 그 후 6% citric acid 250㎕을 넣어 반응을 정지 시킨 후, ethyl acetate 1.5㎖을 첨가하여 320nm에서 흡광도를 측정하였다. 콜라게나아제 저해활성은 시료용액의 첨가군과 무첨가군의 흡광도 감소율로 나타내었다. Collagenase inhibitory activity measurement was carried out by adding 4mM CaCl 2 to 0.1M tris-HCl buffer (pH7.5), 4-phenylazobenzyloxycarbonyl-Pro-Leu-Gly-Pro-D-Arg (0.3mg/ml) ( Sigma, USA) is dissolved in 125 μl of the substrate solution and 50 μl of the 1,000 μg/ml sample solution is mixed with 75 μl of collagenase (0.2 mg/ml) (Sigma, USA) and left at room temperature for 20 minutes. After that, 250 μl of 6% citric acid was added to stop the reaction, and 1.5 ml of ethyl acetate was added to measure the absorbance at 320 nm. Collagenase inhibitory activity was expressed as a decrease in absorbance in the group with and without the sample solution.

Figure pat00006
Figure pat00006

상기 엘라스타아제 저해 활성 측정 결과를 하기 표 6에 나타내었다. The results of measuring the elastase inhibitory activity are shown in Table 6 below.

추출물extract 콜라게나아제 저해 활성(%)Collagenase inhibitory activity (%) 실시예 1Example 1 31.431.4 비교예 1Comparative Example 1 27.727.7 비교예 2Comparative Example 2 20.220.2

상기 실험을 통하여 실시예 1의 조성물이 말오줌나무잎 추출물, 수국잎 추출물의 단일 추출물에 비하여 우수한 에라스타아제 및 콜라게나아제 저해 활성을 나타내어 우수한 피부 주름 개선 효과를 나타내는 것을 확인할 수 있었다. Through the above experiment, it was confirmed that the composition of Example 1 exhibited superior erastase and collagenase inhibitory activity compared to single extracts of horse urinal tree leaf extract and hydrangea leaf extract, thereby exhibiting an excellent skin wrinkle improvement effect.

<실험예 4> 항염증 효능 측정 <Experimental Example 4> Measurement of anti-inflammatory efficacy

항염증 효과를 확인하기 위하여, NO(nitric oxide), iNOS(inducible nitric oxide synthase) 또는 COX-2(cyclooxygenase-2)의 발현의 억제 효과를 측정하였다. In order to confirm the anti-inflammatory effect, the inhibitory effect of NO (nitric oxide), iNOS (inducible nitric oxide synthase) or COX-2 (cyclooxygenase-2) expression was measured.

<실험예 4-1> NO 생성 억제 활성 측정<Experimental Example 4-1> Measurement of NO production inhibitory activity

RAW 264.7 세포로부터 생성된 NO의 양은 griess 시약을 이용하여 세포배양액 중에 존재하는 NO2의 형태로 측정하였다. 96 well plate에 RAW 264.7 세포를 1×105cells/well이 되도록 분주하였다. 37℃, 5% CO2 incubator에서 24시간 배양한 이후 1X PBS로 2번 세척한다. LPS 10μg/㎖을 normal을 제외하고 처리한 후 2시간 이후 1,000 μg/㎖ 농도의 시료용액을 처리하여 24시간 배양한 후 상등액을 얻은 후, 동량의 griess 시약을 첨가하여 96 well plate에서 10분 반응시킨 후 540nm에서의 흡광도를 측정하였다. 상기 생성된 NO의 양을 하기 표 7에 나타내었다,The amount of NO produced from RAW 264.7 cells was measured in the form of NO 2 present in the cell culture medium using griess reagent. RAW 264.7 cells were aliquoted to 1×10 5 cells/well in a 96 well plate. 37 ℃, 5% CO 2 After incubation for 24 hours in an incubator, wash twice with 1X PBS. After treatment with LPS 10μg/ml except for normal, after 2 hours, the sample solution at the concentration of 1,000 μg/ml was treated and cultured for 24 hours to obtain a supernatant. Then, the same amount of griess reagent was added and reacted for 10 minutes in a 96 well plate. After that, the absorbance at 540 nm was measured. The amount of NO produced is shown in Table 7 below,

추출물extract NO 생성량NO production 실시예 1Example 1 59.559.5 비교예 1Comparative Example 1 87.487.4 비교예 2Comparative Example 2 76.976.9

<실험예 4-2> Western blot을 통한 iNOS, COX-2의 활성<Experimental Example 4-2> Activity of iNOS and COX-2 through Western blot

염증인자인 iNOS, COX-2의 활성을 알아보기 위해 cell line (RAW 264.7)을 100mm tissue culture dish에 cell seeding 후 24시간 동안 배양하였다. 배지를 제거한 후 추출물을 농도별로 처리한 배지로 24∼48시간 배양한 후 PBS로 2회 세척한다. Radio-immunoprecipitation assay (RIPA) buffer 10㎖에 complete mini 1 tab를 가한 100㎕로 용해한 후 4℃, 13,200rpm에서 20분간 원심 분리한 후 원심 분리하여 얻은 상층액을 BCA protein assay kit를 사용하여 정량하였다. 20㎕의 단백질을 10% SDS-PAGE상에서 전기영동 하여 분리한 후 분리된 단백질은 polyvinylidene fluoride (PVDF) membrane에 옮겨 blocking buffer (5% skim milk in TBST)을 제조하여 실온에서 1시간 blocking을 실시하였다. 1차 항체를 희석하여 4℃에서 over night 후 다시 10분 간격으로 tris-buffered saline and tween 20 (TBST)로 3회 세척한다. 2차 항체를 1:1,000로 희석하여 실온에서 2시간 반응 후 3회 세척하여 Davinch-ChemiTM Imager CAS-400SM 기기를 사용해 밴드를 확인 및 정량하였다. 상기 실험 결과를 도 1에 나타내었다. In order to examine the activity of inflammatory factors iNOS and COX-2, the cell line (RAW 264.7) was cultured for 24 hours after cell seeding in a 100 mm tissue culture dish. After removing the medium, the extract is incubated for 24 to 48 hours in a medium treated with each concentration, and then washed twice with PBS. Radio-immunoprecipitation assay (RIPA) buffer 10ml was dissolved with 100 μl of complete mini 1 tab added, centrifuged at 4℃, 13,200rpm for 20 minutes, and the supernatant obtained by centrifugation was quantified using a BCA protein assay kit. . After separating 20 μl of protein by electrophoresis on 10% SDS-PAGE, the separated protein was transferred to a polyvinylidene fluoride (PVDF) membrane to prepare a blocking buffer (5% skim milk in TBST), and blocking was performed at room temperature for 1 hour. . Dilute the primary antibody and wash 3 times with tris-buffered saline and tween 20 (TBST) every 10 minutes again after over night at 4°C. The secondary antibody was diluted 1:1,000, reacted at room temperature for 2 hours, washed 3 times, and bands were identified and quantified using a Davinch-Chemi TM Imager CAS-400SM instrument. The experimental results are shown in FIG. 1 .

도 1에서 보는 바와 같이, LPS에 의해 증가된 iNOS와 COX-2의 단백질 발현양이 농도 의존적으로 감소하였으며 100 ㎍/㎖ 농도에서 각각 24.6%, 56.2%의 저해활성을 나타내었다. 대조군인 비타민 C 와 비교하였을 때 iNOS는 대조군과 유의한 결과를 확인하였으며, COX-2는 비타민 C보다 단백질 발현양이 억제되었음을 확인하였다. As shown in FIG. 1 , the protein expression levels of iNOS and COX-2 increased by LPS decreased in a concentration-dependent manner, and inhibitory activities of 24.6% and 56.2% were exhibited at a concentration of 100 μg/ml, respectively. When compared with the control group, vitamin C, iNOS showed a significant result compared to the control group, and COX-2 showed more suppressed protein expression than vitamin C.

<실험예 4-3> RT-PCR을 통한 iNOS, COX-2의 활성 <Experimental Example 4-3> Activity of iNOS and COX-2 through RT-PCR

Cell line RAW 264.7을 100mm culture dish에 1×106cells/well로 cell seeding하여 24시간 동안 배양한 후 LPS를 1μg/㎖ 농도로 2시간 처리해준 뒤 추출물을 농도별로 처리하여 24시간 동안 배양하였다. 배지 상등액을 제거한 후 trizol lysis buffer를 well에 1㎖씩 분주하여 세포를 lysis한 후 chloroform 200㎕를 분주하여 20초간 위아래로 흔들어주었다. 그 후, 13,200rpm에서 20분간 원심 분리하여 상층액을 isopropanol 500㎕가 들어있는 튜브에 옮겨 섞었다. 다시 13,200rpm에서 20분간 원심분리하였고, 그 상층액을 제거한 후 75% EtOH-diethylpyrocarbonate (DEPC) water를 각 튜브에 1㎖씩 분주하여 13,200rpm에서 5분간 원심분리한 뒤 상층액을 제거한 뒤 실온에서 건조하였다. DEPC를 처리한 증류수를 50㎕씩 분주하여 녹인 후 96 well plate에 RNA 5㎕와 멸균수 195㎕를 첨가하여 260nm, 280nm에서 각각 흡광도를 측정하여 total RNA양을 측정하였다. Oligo (dT) 15 primer (500μg/㎖) 1㎕, 추출한 RNA (2μg)와 nuclease free water로 10㎕를 맞추고 75℃에서 5분간 반응시킨 후 5X reaction buffer, MgCl2, PCR nucleotide mix, rnasin inhibitor, reverse transcriptase, nuclease free water를 첨가하여 25℃에서 5분, 42℃에서 60분, 70℃에서 15분간 반응시켜 cDNA를 합성하였다. Cell line RAW 264.7 was seeded in a 100 mm culture dish at 1×10 6 cells/well and cultured for 24 hours, then treated with LPS at a concentration of 1 μg/ml for 2 hours, and the extracts were treated by concentration and cultured for 24 hours. After removing the medium supernatant, 1 ml of trizol lysis buffer was dispensed into each well to lyse the cells, and 200 μl of chloroform was dispensed and shaken up and down for 20 seconds. Then, centrifuged at 13,200 rpm for 20 minutes, and the supernatant was transferred to a tube containing 500 μl of isopropanol and mixed. After centrifugation again at 13,200 rpm for 20 minutes, after removing the supernatant, 1 ml of 75% EtOH-diethylpyrocarbonate (DEPC) water was dispensed into each tube and centrifuged at 13,200 rpm for 5 minutes, after which the supernatant was removed and cooled at room temperature. dried. After dissolving 50 μl of distilled water treated with DEPC, 5 μl of RNA and 195 μl of sterile water were added to a 96-well plate, and absorbance was measured at 260 nm and 280 nm, respectively, to measure the total RNA amount. Oligo (dT) 15 primer (500μg/ml) 1μl, extracted RNA (2μg) and nuclease free water 10μl, react at 75℃ for 5 minutes, 5X reaction buffer, MgCl 2 , PCR nucleotide mix, rnasin inhibitor, Reverse transcriptase and nuclease free water were added and reacted at 25°C for 5 minutes, 42°C for 60 minutes, and at 70°C for 15 minutes to synthesize cDNA.

iNOS, COX-2의 mRNA 발현을 알아보기 위하여 polymerase chain reaction (PCR)을 실시하였다. 실험에 사용한 primer sequences는 하기 표 8과 같다. PCR tube에 5X green Go Taq flexi buffer, MgCl2, PCR nucleotide mix (10mM), primer, Go Taq DNA polymerase, nuclease free water, 합성한 cDNA를 첨가하여 잘 섞은 후 PCR을 실행하였다. GAPDH, iNOS는 96℃에서 2분, 96℃에서 10초, 64℃에서 30초, 72℃에서 1분, 72℃에서 10분 (40 cycles), COX-2는 96℃에서 2분, 94℃에서 10초, 51℃에서 30초, 72℃에서 1분, 72℃에서 10분 (40 cycles), PCR로 합성시킨 후 0.002% ethidium bromide를 첨가한 1.5% agarose gel을 100V에서 40분간 전기영동한 후 LAS 4,000을 이용하여 밴드를 확인하여 분석 정량하였다. Polymerase chain reaction (PCR) was performed to examine the mRNA expression of iNOS and COX-2. The primer sequences used in the experiment are shown in Table 8 below. 5X green Go Taq flexi buffer, MgCl 2 , PCR nucleotide mix (10mM), primer, Go Taq DNA polymerase, nuclease free water, and synthesized cDNA were added to the PCR tube, mixed well, and then PCR was performed. GAPDH, iNOS at 96°C for 2 minutes, 96°C for 10 seconds, 64°C for 30 seconds, 72°C for 1 minute, 72°C for 10 minutes (40 cycles), COX-2 at 96°C for 2 minutes, 94°C 10 sec at 51 °C for 30 sec, 72 °C for 1 min, 72 °C for 10 min (40 cycles), after synthesis by PCR, 1.5% agarose gel with 0.002% ethidium bromide was electrophoresed at 100 V for 40 min. Then, the band was identified using LAS 4,000 and analyzed and quantified.

GeneGene PrimerPrimer Sequence (5’ →3’)Sequence (5’ →3’) COX-2COX-2 sensesense GGA GAG ACT ATC AAG ATA GTGGA GAG ACT ATC AAG ATA GT anti-senseanti-sense ATG GTC AGT AGA CTT TTA CAATG GTC AGT AGA CTT TTA CA iNOSiNOS sensesense AAT GGC AAC ATC AGG TCG GCC ATC ACTAAT GGC AAC ATC AGG TCG GCC ATC ACT anti-senseanti-sense GCT GTG TGT CAC AGA AGT CTC GAA CTCGCT GTG TGT CAC AGA AGT CTC GAA CTC

상기 분석 결과를 도 2에 나타내었다. The analysis results are shown in FIG. 2 .

상기 도 2에서 보는 바와 같이, LPS에 의해 증가된 iNOS와 COX-2의 mRNA 발현양이 감소된 것을 확인할 수 있었으며, 대조군인 비타민 C와 비교하였을 때 100 μg/㎖ 의 농도에서 유의한 결과를 확인하였다.As shown in FIG. 2, it was confirmed that the mRNA expression levels of iNOS and COX-2 increased by LPS were decreased, and a significant result was confirmed at a concentration of 100 μg/ml when compared with vitamin C, a control. did.

상기 실험을 통하여 실시예 1의 조성물이 말오줌나무잎 추출물, 수국잎 추출물의 단일 추출물에 비하여 우수한 NO(nitric oxide), iNOS(inducible nitric oxide synthase) 또는 COX-2(cyclooxygenase-2)의 발현의 억제 효과를 나타내어 높은 항염증 활성을 나타내는 것을 확인할 수 있었다. Through the above experiment, the composition of Example 1 showed superior NO (nitric oxide), iNOS (inducible nitric oxide synthase) or COX-2 (cyclooxygenase-2) expression compared to single extracts of horse urinal tree leaf extract and hydrangea leaf extract. It was confirmed that it exhibited an inhibitory effect and exhibited high anti-inflammatory activity.

Claims (6)

말오줌나무잎 추출물 및 수국잎 추출물을 유효성분으로 포함하는 것을 특징으로 하는 항산화, 피부 미백, 주름 개선 또는 피부 염증성 질환 개선용 화장료 조성물.
A cosmetic composition for antioxidation, skin whitening, wrinkle improvement, or skin inflammatory disease improvement, characterized in that it comprises a horse urinal leaf extract and hydrangea leaf extract as active ingredients.
제1항에 있어서,
상기 추출물은 물, C1 ~ C4의 알코올, 프로필렌글리콜, 부틸렌글리콜, 글리세린, 아세톤, 에틸 아세테이트, 클로로포름, 부틸 아세테이트, 디에틸에테르, 디클로로메탄, 헥산 또는 이들의 혼합물을 용매로 사용하여 추출한 것을 특징으로 하는 화장료 조성물.
According to claim 1,
The extract is extracted using water, C 1 to C 4 alcohol, propylene glycol, butylene glycol, glycerin, acetone, ethyl acetate, chloroform, butyl acetate, diethyl ether, dichloromethane, hexane or a mixture thereof as a solvent. A cosmetic composition, characterized in that
제1항에 있어서,
상기 말오줌나무잎 추출물 및 수국잎 추출물은 1 : 0.1 ~ 10 중량비로 포함되는 것을 특징으로 하는 화장료 조성물.
According to claim 1,
The extract of the horse pee tree leaf and the hydrangea leaf extract is 1: 0.1 to 10 by weight of the cosmetic composition, characterized in that it is included.
제1항에 있어서,
상기 조성물은 DPPH(1-1-diphenyl-2-picryl-hydrazyl), ABTS(2,2'-azino-bis-3-ethylbenzothiazoline-6-sulphonic acid) 라디칼(radical) 또는 슈퍼옥사이드 음이온 라디칼(superoxide anion radical) 활성을 저해하는 것을 특징으로 하는 화장료 조성물.
According to claim 1,
The composition is DPPH (1-1-diphenyl-2-picryl-hydrazyl), ABTS (2,2'-azino-bis-3-ethylbenzothiazoline-6-sulphonic acid) radical (radical) or superoxide anion radical (superoxide anion) radical) a cosmetic composition, characterized in that it inhibits activity.
제1항에 있어서,
상기 조성물은 티로시나아제(Tyrosinase), 엘라스타아제(Elastase), 콜라게나아제(Collagenase)의 발현을 억제하는 것을 특징으로 하는 화장료 조성물.
According to claim 1,
The composition is a cosmetic composition, characterized in that it inhibits the expression of tyrosinase (Tyrosinase), elastase (Elastase), collagenase (Collagenase).
제1항에 있어서,
상기 조성물은 NO(nitric oxide), iNOS(inducible nitric oxide synthase) 또는 COX-2(cyclooxygenase-2)의 발현을 억제하는 것을 특징으로 하는 화장료 조성물.
According to claim 1,
The composition is a cosmetic composition, characterized in that it inhibits the expression of NO (nitric oxide), iNOS (inducible nitric oxide synthase) or COX-2 (cyclooxygenase-2).
KR1020200004587A 2020-01-14 2020-01-14 Cosmetic composition containing natural complex extracts as active ingredient KR102343705B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020200004587A KR102343705B1 (en) 2020-01-14 2020-01-14 Cosmetic composition containing natural complex extracts as active ingredient

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020200004587A KR102343705B1 (en) 2020-01-14 2020-01-14 Cosmetic composition containing natural complex extracts as active ingredient

Publications (2)

Publication Number Publication Date
KR20210091430A true KR20210091430A (en) 2021-07-22
KR102343705B1 KR102343705B1 (en) 2021-12-24

Family

ID=77158030

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020200004587A KR102343705B1 (en) 2020-01-14 2020-01-14 Cosmetic composition containing natural complex extracts as active ingredient

Country Status (1)

Country Link
KR (1) KR102343705B1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220169298A (en) * 2021-06-18 2022-12-27 경북대학교 산학협력단 Anti-oxidant, anti-bacterial, anti-hypertension, or anti-gout composition comprising extract of Sambucus sieboldiana var. pendula as an active ingredient
WO2023080724A1 (en) * 2021-11-04 2023-05-11 코스맥스바이오 주식회사 Composition, for preventing, relieving, or treating respiratory disease, having hydrangenol or phyllodulcin as active ingredient

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001122730A (en) * 1999-10-26 2001-05-08 Ichimaru Pharcos Co Ltd Cosmetic composition containing moisturizing plant extract
KR20060091355A (en) * 2005-02-14 2006-08-21 이영열 Cosmetic compositions for skin-whitening comprising plant extracts and aroma essential oil as active ingredients
KR20090081178A (en) * 2008-01-23 2009-07-28 주식회사 사임당화장품 Cosmetic composition containing wild flower extracts
KR20100031372A (en) * 2008-09-12 2010-03-22 김경자 Cosmetic composition for skin beauty and manufacturing method thereof
KR101492074B1 (en) 2012-12-24 2015-02-12 재단법인 홍천메디칼허브연구소 Compositions containing an extract of hydrangea macrophylla for. otaksa for skin whitening
KR20160024675A (en) * 2014-08-26 2016-03-07 이스트힐(주) Cosmetic composition for skin-moisturization comprising the extract of hydrangea macrophylla var. thunbergii and manufacture of the same
JP2018203628A (en) * 2017-05-30 2018-12-27 一丸ファルコス株式会社 Cosmetic composition or food and drink composition
US20190008747A1 (en) * 2012-12-27 2019-01-10 Hayashibara Co., Ltd. External dermal composition for anti-ageing and method for producing the same

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001122730A (en) * 1999-10-26 2001-05-08 Ichimaru Pharcos Co Ltd Cosmetic composition containing moisturizing plant extract
KR20060091355A (en) * 2005-02-14 2006-08-21 이영열 Cosmetic compositions for skin-whitening comprising plant extracts and aroma essential oil as active ingredients
KR20090081178A (en) * 2008-01-23 2009-07-28 주식회사 사임당화장품 Cosmetic composition containing wild flower extracts
KR20100031372A (en) * 2008-09-12 2010-03-22 김경자 Cosmetic composition for skin beauty and manufacturing method thereof
KR101492074B1 (en) 2012-12-24 2015-02-12 재단법인 홍천메디칼허브연구소 Compositions containing an extract of hydrangea macrophylla for. otaksa for skin whitening
US20190008747A1 (en) * 2012-12-27 2019-01-10 Hayashibara Co., Ltd. External dermal composition for anti-ageing and method for producing the same
KR20160024675A (en) * 2014-08-26 2016-03-07 이스트힐(주) Cosmetic composition for skin-moisturization comprising the extract of hydrangea macrophylla var. thunbergii and manufacture of the same
JP2018203628A (en) * 2017-05-30 2018-12-27 一丸ファルコス株式会社 Cosmetic composition or food and drink composition

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220169298A (en) * 2021-06-18 2022-12-27 경북대학교 산학협력단 Anti-oxidant, anti-bacterial, anti-hypertension, or anti-gout composition comprising extract of Sambucus sieboldiana var. pendula as an active ingredient
WO2023080724A1 (en) * 2021-11-04 2023-05-11 코스맥스바이오 주식회사 Composition, for preventing, relieving, or treating respiratory disease, having hydrangenol or phyllodulcin as active ingredient

Also Published As

Publication number Publication date
KR102343705B1 (en) 2021-12-24

Similar Documents

Publication Publication Date Title
JP5850929B2 (en) Composition for improving the appearance of the skin by stimulating MAGP-1
EP3060228B1 (en) Lipid extract of passion fruit seeds
JP2020532560A (en) Cosmetic composition containing extract of Dendrobium candidam flower
EP2654766A1 (en) Avocado flesh and/or skin extract rich in polyphenols and cosmetic, dermatological and nutraceutical compositions comprising same
EP2654762B1 (en) Extract of the aerial parts of gynandropsis gynandra and cosmetic, dermatoligic and pharmaceutic compositions comprising the extract
KR101387308B1 (en) Skin whitening composition by using of dendropanax morbifera ferment extract
US11484559B2 (en) Kapok tree flower extract, and cosmetic, pharmaceutical or dermatological compositions containing same
TW201206494A (en) Use of Tiliacora triandra in cosmetics and compositions thereof
KR102343705B1 (en) Cosmetic composition containing natural complex extracts as active ingredient
KR20200104158A (en) Cosmetic composition comprising centella asiatica extracts cultivated by aquaponics
KR101489935B1 (en) Method for preparing mugwort extract and cosmetic composition comprising mugwort extract prepared therefrom
KR100864915B1 (en) Composition comprising mixed extract of japanese apricot and pear blossom having anti-oxidative activity
KR102612017B1 (en) Composition for skin improvement comprising multiple extract
CA3173694C (en) Moringa peregrina seed extract rich in 2,5-diformylfuran, process for obtaining same and use thereof in cosmetic compositions
KR102646545B1 (en) Cosmetic composition for skin whitening or skin barrier improvement comprising Hosta longipes extract
KR102611916B1 (en) Composition for skin improvement comprising multiple extract
KR102400179B1 (en) Cosmetic composition antimicroboal, antioxidation, whitening or anti-inflammation comprising artemisia capillaris thunberg and olive extract
WO2020203933A1 (en) Antiaging agent, antioxidant, antiinflammatory agent and whitening agent, and cosmetic
KR101534911B1 (en) Cosmetic composition comprising the extract of Juniperus rigida Sieb. or Juniper berry as active ingredient
KR20210083236A (en) Composition for preventing hair loss and improving the scalp
KR102057376B1 (en) Composition for skin whitening comprising extract of stichopus japonicas red
KR102610308B1 (en) Composition for promoting hair growth or preventing hair loss comprising Stephanandra incisa extract
KR102504878B1 (en) cosmetic composition having anti-inflammatory and skin soothing and effects and improvement of skin itching containing fermented extracts of Campsis grandiflora, Plum blossom, Quercus acuta THUNB
KR102329921B1 (en) Composition for Improving Skin Conditions Extracts of Swallow&#39;s Nest Fermented by Novel Strain of Lactobacillus sp. as Active Ingredient
KR20230006131A (en) Cosmetic composition having skin whitening effect

Legal Events

Date Code Title Description
E701 Decision to grant or registration of patent right
GRNT Written decision to grant